Mason Street Advisors LLC purchased a new stake in Anika Therapeutics Inc. (NASDAQ:ANIK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,802 shares of the company’s stock, valued at approximately $150,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas boosted its stake in Anika Therapeutics by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 2,037 shares of the company’s stock valued at $109,000 after buying an additional 252 shares during the period. BlackRock Inc. boosted its stake in Anika Therapeutics by 99.0% in the second quarter. BlackRock Inc. now owns 2,032 shares of the company’s stock valued at $109,000 after buying an additional 1,011 shares during the period. Paloma Partners Management Co purchased a new stake in Anika Therapeutics during the second quarter valued at $233,000. Bank of Montreal Can purchased a new stake in Anika Therapeutics during the second quarter valued at $247,000. Finally, AHL Partners LLP purchased a new stake in Anika Therapeutics during the second quarter valued at $247,000. Institutional investors own 77.84% of the company’s stock.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 44.50 on Friday. The stock’s 50 day moving average price is $47.21 and its 200 day moving average price is $48.09. Anika Therapeutics Inc. has a 12-month low of $32.76 and a 12-month high of $54.96. The company has a market capitalization of $657.58 million, a PE ratio of 19.42 and a beta of 1.49.
Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 27th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. The company earned $26.60 million during the quarter, compared to the consensus estimate of $24.75 million. Anika Therapeutics had a return on equity of 17.24% and a net margin of 33.77%. The firm’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.51 EPS. On average, equities research analysts forecast that Anika Therapeutics Inc. will post $2.00 earnings per share for the current year.
Separately, Zacks Investment Research cut Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 11th.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.